The present disclosure relates to a method for vacuum expansion of a paste prior to freeze-drying said paste to achieve a dry paste composition which reconstitutes efficiently to form a flowable paste upon addition of an aqueous medium. The present disclosure further relates to a syringe for retaining a dry paste composition in a vacuum.

The present invention relates to a coating comprising at least one biodegradable polymer, wherein the polymer comprises at least one or a blend of a poly (ester amide) (PEA) having a chemical formula described by structural formula (II), wherein; R.sub.1 is independently selected from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, —(R.sub.9—CO—O—R.sub.10—O—CO—R.sub.9)—, CH R.sub.11—O—CO—R.sub.12—COOCR.sub.11— and combinations thereof; R.sub.3 and R.sub.4 in a single co-monomer m or p, respectively, are independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, (C.sub.6-C.sub.10)aryl, (C.sub.1C.sub.6)alkyl, —(CH.sub.2)SH, —(CH.sub.2).sub.2S(CH.sub.3), CH.sub.2OH, —CH(OH)CH.sub.3, —(CH.sub.2).sub.4NH.sub.3+, ˜(CH.sub.2).sub.3NHC(═NH.sub.2+)NH.sub.2, —CH.sub.2COOH, (CH.sub.2)COOH, —CH.sub.2—CO—NH.sub.2—CH.sub.2CH.sub.2—CO—NH.sub.2, —CH.sub.2CH.sub.2COOH, CH.sub.3—CH.sub.2—CH(CH.sub.3)—, formula (a), HO-.sub.P-Ph-CH.sub.2—, (CH.sub.3).sub.2—CH—, Ph- NH—, NH—(CH.sub.2).sub.3—C—, NH—CH═N—CH═C—CH.sub.2—. R.sub.5 or R.sub.6 are independently selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols or from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, alkyloxy, oligoethyleneglycol with a Mw ranging from 44 Da up to 700 Da, —CH.sub.2—CH—(CH.sub.2OH).sub.2, CH.sub.2CH(OH)CH.sub.2 whereby R.sub.5 and R.sub.6 are non identical. R.sub.7 is hydrogen, (C.sub.6-C.sub.10) aryl, (C.sub.1C.sub.6) alkyl or a protecting group such as benzyl- or a bioactive agent; R.sub.8 is independently (C.sub.1-C.sub.20) alkyl or (C.sub.2-C.sub.20)alkenyl; R.sub.9 or R.sub.10 are independently selected from C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene and R.sub.11 or R.sub.12 are independently selected from H, methyl, C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene.

##STR00001##

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.

Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

The present invention relates to biomaterials that interact with and regulate immune functions, as well as implantable materials and devices. In one embodiment, the present invention provides an implantable medical device comprising a biomaterial coated with one or more CD200 molecules. In another embodiment, the present invention provides a method of treating inflammation by administering a composition comprising one or more biomaterials that inhibit immune reactivity.

Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as Bacillus anthracis and Yersenia pestis. The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications.

A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.

Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers.